CO2023004837A2 - Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos - Google Patents

Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos

Info

Publication number
CO2023004837A2
CO2023004837A2 CONC2023/0004837A CO2023004837A CO2023004837A2 CO 2023004837 A2 CO2023004837 A2 CO 2023004837A2 CO 2023004837 A CO2023004837 A CO 2023004837A CO 2023004837 A2 CO2023004837 A2 CO 2023004837A2
Authority
CO
Colombia
Prior art keywords
canine
feline
oncostatin
receptor beta
beta antibodies
Prior art date
Application number
CONC2023/0004837A
Other languages
English (en)
Inventor
Gary Francis Bammert
Andrea Joy Gonzales
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2023004837A2 publication Critical patent/CO2023004837A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona un anticuerpo aislado, o una porción de unión al antígeno de este, que se une específicamente al receptor de oncostatina M beta (OSMR-β) canino o felino o a ambos, en donde el anticuerpo antagoniza la transducción de señales mediada por IL-31 o la transducción de señales mediada por OSM o ambas en una célula canina y/o felina.
CONC2023/0004837A 2020-10-19 2023-04-18 Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos CO2023004837A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063093607P 2020-10-19 2020-10-19
PCT/US2021/055366 WO2022086837A1 (en) 2020-10-19 2021-10-18 Antibodies to canine and feline oncostatin m receptor beta and uses thereof

Publications (1)

Publication Number Publication Date
CO2023004837A2 true CO2023004837A2 (es) 2023-05-19

Family

ID=78622023

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0004837A CO2023004837A2 (es) 2020-10-19 2023-04-18 Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos

Country Status (17)

Country Link
US (1) US20220177594A1 (es)
EP (1) EP4229087A1 (es)
JP (1) JP2023546161A (es)
KR (1) KR20230092978A (es)
CN (1) CN116406378A (es)
AR (1) AR123839A1 (es)
AU (1) AU2021364308A1 (es)
CA (1) CA3196925A1 (es)
CL (1) CL2023001108A1 (es)
CO (1) CO2023004837A2 (es)
EC (1) ECSP23028951A (es)
IL (1) IL302147A (es)
MX (1) MX2023004500A (es)
PE (1) PE20231210A1 (es)
TW (1) TW202221039A (es)
UY (1) UY39474A (es)
WO (1) WO2022086837A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736378A (en) * 1991-09-12 1998-04-07 The Scripps Research Institute Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
KR100788219B1 (ko) 1999-03-18 2007-12-26 메르크 파텐트 게엠베하 혈소판 부착 차단용 단백질
US6790639B2 (en) 2000-02-29 2004-09-14 Pfizer Inc. Mammalian osteoregulins
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
EP2258723A1 (en) * 2009-06-02 2010-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of oncostatin M receptor ß mediated heart failure
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
ES2692657T3 (es) * 2013-05-30 2018-12-04 Kiniksa Pharmaceuticals, Ltd. Proteínas de enlace al antígeno del receptor de oncastatina
WO2019177697A2 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use

Also Published As

Publication number Publication date
US20220177594A1 (en) 2022-06-09
PE20231210A1 (es) 2023-08-17
CN116406378A (zh) 2023-07-07
CA3196925A1 (en) 2022-04-28
AU2021364308A1 (en) 2023-05-18
EP4229087A1 (en) 2023-08-23
AR123839A1 (es) 2023-01-18
IL302147A (en) 2023-06-01
UY39474A (es) 2022-06-30
MX2023004500A (es) 2023-05-10
CL2023001108A1 (es) 2023-11-24
AU2021364308A9 (en) 2023-07-13
WO2022086837A1 (en) 2022-04-28
TW202221039A (zh) 2022-06-01
JP2023546161A (ja) 2023-11-01
ECSP23028951A (es) 2023-07-31
KR20230092978A (ko) 2023-06-26

Similar Documents

Publication Publication Date Title
CU24537B1 (es) Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
CL2016002624A1 (es) Anticuerpos humanos que se unen al gen 3 de activación linfocitaria (lag-3) y los usos de estos (divisional sol. n°0308-2011)
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
CU20180135A7 (es) Anticuerpos monoclonales aislados que compiten por la unión a tau con el anticuerpo 3d6
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MA31138B1 (fr) Anticorps humains de haute affinite diriges contre le recepteur humain de l'il-4
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
MA32802B1 (fr) Anticorps humains à affinité élevée pour le récepteur de il-4 humain
CR11691A (es) Anticuerpos monoclonales contra la proteína rgm a y sus usos
CL2021000942A1 (es) Anticuerpos anti-npr1 y usos relacionados.
RS54056B1 (en) ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
HN2010000880A (es) Nuevos anticuerpos especificos de los peptidos b-amiloides y sus usos como agentes de diagnostico o drogas
CL2009000586A1 (es) Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
CL2021002710A1 (es) Anticuerpos biespecíficos
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
CU20210099A7 (es) Anticuerpos de receptor de péptido natriurético 1
BR112022011669A2 (pt) Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica
CL2022002327A1 (es) Métodos de producción de células que expresan receptores antigénicos quiméricos
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
CL2020001732A1 (es) Constructo de anticuerpo biespecífico dirigido a muc17 y cd3
CO2023004837A2 (es) Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos
ZA202206438B (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
PE20221462A1 (es) Composiciones y metodos para la activacion de integrinas
BR112021020677A2 (pt) Anticorpos contra receptores de antígeno quimérico derivados de 4g7